Safety and immunogenicity of the intradermal Thai red cross (2-2-2-0-1-1) post exposure vaccination regimen in the Indian population using purified chick embryo cell rabies vaccine.
OBJECTIVE
To test the immunogenicity of the WHO recommended "2-2-2-0-1-1" post-exposure rabies vaccination regimen in Indian subjects to determine the feasibility of replacing crude sheep brain nerve tissue rabies vaccine with modern tissue culture rabies vaccine at major anti-rabies treatment centers throughout India.


METHODS
Purified chick embryo cell vaccine (PCECV) was administered in the dosage of 0.1 mL per site to 53 Indian subjects.


RESULTS
All subjects produced rabies antibodies above 0.5 IU/mL by day 14 post-vaccination. Only minor adverse reactions including swelling (6.6%), erythema (5.4%) and pain (1.4%) were observed for which no treatment was required.


CONCLUSIONS
This study demonstrated that PCECV is safe and highly immunogenic in Indian subjects when administered intradermally as 0.1 mL/site using the "2-2-2-0-1-1" post-exposure regimen.
Chhabra
Mala
M
National Institute of Communicable Diseases, Sham Nath Marg, New Delhi 110 054, India. malachhabra@yahoo.co.in
Ichhpujani
R L
RL
Bhardwaj
M
M
Tiwari
K N
KN
Panda
R C
RC
Lal
S
S
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002642:Chick Embryo; D006801:Humans; D007115:Immunization Schedule; D007136:Immunoglobulins / Q000032:analysis; D007194:India; D007271:Injections, Intradermal; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D012011:Red Cross; D012449:Safety; D013785:Thailand; D014611:Vaccination
D000914:Antibodies, Viral; D007136:Immunoglobulins; D011819:Rabies Vaccines